Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in heart failure with preserved or mildly reduced ejection fraction
NL-OMON52867Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Finerenone with Placebo (2 arms). Primary endpoint: Composite cardiovascular endpoint. Started Oct 2020; status: recruiting.
02
Drugs
finerenone
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON52867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52867.